Product
Ubrogepant
Aliases
Ubrelvy, UBRELVY
Name
UBRELVY
INN Name
ubrogepant
FDA Approved
Yes
7 clinical trials
1 organization
2 indications
1 document
Indication
Healthy Control ParticipantsIndication
MigraineClinical trial
A Phase 1 Lactation Study in Healthy Adult Lactating Female Subjects One to Six Months Post-Partum to Evaluate the Pharmacokinetics and Safety of Ubrogepant and AtogepantStatus: Completed, Estimated PCD: 2024-02-22
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)Status: Recruiting, Estimated PCD: 2026-05-05
Clinical trial
A Phase 4, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of the Concomitant Use of Ubrogepant for the Acute Treatment of Migraine in Subjects Taking Atogepant for the Preventive Treatment of Episodic MigraineStatus: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the ProdromeStatus: Completed, Estimated PCD: 2022-04-19
Clinical trial
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)Status: , Estimated PCD: 2027-03-09
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label ExtensionStatus: Recruiting, Estimated PCD: 2027-09-03
Clinical trial
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and CapsaicinStatus: Completed, Estimated PCD: 2023-03-15
Document
DailyMed Label: UBRELVYOrganization
Allergan, Inc.